## **Division Laboratory Measurement Uncertainty Schedule**

ANALYTES <sup>1</sup>	MEASUREMENT UNCERTAINTY	
(a) acepromazine [2-(1-hydroxyethyl) promazine sulfoxide]	No greater than +/- 1 ng/mL (urine)	
(b) albuterol	No greater than +/- 0.13 ng/mL (urine)	
(c) betamethasone	No greater than +/- 5.3 pg/mL (serum) <sup>2</sup>	
(d) butorphanol	No greater than +/- 0.31 ng/mL (serum) (Not tested for in urine)	
(e) clenbuterol	No greater than +/- 21 pg/mL (urine)	
(f) dantrolene (5-hydroxydantrolene)	No greater than +/- 11 pg/mL (serum)	
(g) detomidine (carboxydetomidine)	No greater than +/- 1 ng/mL (urine) <sup>3</sup>	
(h) dexamethasone	No greater than +/- 4.7 pg/mL (serum) <sup>4</sup>	
(i) diclofenac	No greater than +/- 0.39 ng/mL (serum)	
(j) dimethyl sulfoxide (DMSO)	No greater than +/- 0.7 μg/mL (serum)	
(k) firocoxib	No greater than +/- 1.7 ng/mL (serum)	
(l) furosemide	No greater than +/- 3.8 ng/mL (serum) No greater than +/- 0.0010 sp. g. (urine)	
(m) glycopyrrolate	No greater than +/- 0.44 pg/mL (serum)	
(n) isoflupredone	No greater than +/- 20 pg/mL (serum)	
(o) lidocaine (OH-lidocaine)	No greater than +/- 1.7 pg/mL (serum)	
(p) mepivacaine (hydroxymepivacaine)	No greater than +/- 1.5 ng/mL (urine)	
(q) methocarbamol	No greater than +/- 0.11 ng/mL (serum)	
(r) methylprednisolone	No greater than +/- 15 pg/mL (serum)	
(s) omeprazole (omeprazole sulfide)	No greater than +/- 0.09 ng/mL (urine)	
(t) prednisolone	No greater than +/- 0.2 ng/mL (serum)	
(u) procaine penicillin (procaine)	No greater than +/- 5.0 ng/mL (serum)	

<sup>&</sup>lt;sup>1</sup> Analytes include substances, their corresponding metabolites, and/or markers.

Effective Date: 05-20-2021

<sup>&</sup>lt;sup>2</sup> Measurement uncertainty for betamethasone established at a concentration of 50 pg/mL.

<sup>&</sup>lt;sup>3</sup> Measurement uncertainty for detomidine established at a concentration of 5 ng/mL.

 $<sup>^{4}</sup>$  Measurement uncertainty for dexamethasone established at a concentration of 50 pg/mL.

(v) triamcinolone acetonide	No greater than +/- 18 pg/mL (serum)
(w) xylazine	No greater than +/- 1.6 pg/mL (serum)
(x) ketoprofen	No greater than +/- 0. 21 ng/mL (primary; serum) No greater than +/- 0.15 ng/mL (secondary; serum) <sup>5</sup>
(y) phenylbutazone	No greater than +/- 0.19 μg/mL (primary; serum) No greater than +/- 0.025 μg/mL (secondary; serum)
(z) flunixin	No greater than +/- 1.7 ng/mL (primary; serum) No greater than +/- 0.12 ng/mL (secondary; serum)

Analyte	Matrix	Sex	MU (+/-)
Stanozolol	Urine	N/A	0.17 ng/mL
16β-hydroxystanozolol	Urine	N/A	0.17 ng/mL
Boldenone	Urine	Males other than Geldings	1.6 ng/mL
Nandrolone	Urine	Geldings and Females	$2.0 \text{ ng/mL}^6$
5α-oestrane-3β,17α-diol	Urine	Males other than Geldings	1.5 ng/mL
Testosterone	Urine	Geldings	2.1 ng/mL
Testosterone	Urine	Females	2.6 ng/mL

Effective Date: 05-20-2021

<sup>&</sup>lt;sup>5</sup> Measurement uncertainties for ketoprofen established at a concentration of 1.5 ng/mL.

 $<sup>^{6}</sup>$  Measurement uncertainty for nandrolone established at a concentration of 20 ng/mL.